Regeneron Pharmaceuticals Investor Presentation — November 2020

Document content

CORPORATE PRESENTATION

2NOTE REGARDING FORWARD -LOOKING STATEMENTS

AND NON -GAAP FINANCIAL MEASURES

This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual events orresults may differ materially from

these forward -looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended toidentify such forward -looking statements, although notallforward -looking statements

contain these identifying words .These statements concern, and these risks and uncertainties include, among others, theimpact ofSARS -CoV-2(the virus that hascaused theCOVID -19pandemic) onRegeneron's business and itsemployees, collaborators, and

suppliers and other third parties onwhich Regeneron relies, Regeneron's and itscollaborators’ ability tocontinue toconduct research and clinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed orotherwise

commercialized byRegeneron and/or itscollaborators (collectively, "Regeneron’s Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andRegeneron’s product candidates andresearch and

clinical programs now underway orplanned, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab), Libtayo®(cemiplimab), Praluent®(alirocumab), Kevzara®(sarilumab), InmazebTM(atoltivimab ,maftivimab ,andodesivimab -ebgn ),REGN -COV 2,

fasinumab, evinacumab, garetosmab, pozelimab ,Regeneron’s oncology programs (including itscostimulatory bispecific portfolio), Regeneron’s earlier -stage programs, andtheuseofhuman genetics inRegeneron’s research programs ;safety issues resulting from the

administration ofRegeneron’s Products andproduct candidates inpatients, including serious complications orside effects inconnection with theuseofRegeneron’s Products andproduct candidates inclinical trials ;thelikelihood, timing, andscope ofpossible regulatory

approval andcommercial launch ofRegeneron’s product candidates andnew indications forRegeneron’s Products including without limitation EYLEA, Dupixent, Libtayo, Praluent, Kevzara, Inmazeb ,REGN -COV 2,fasinumab, evinacumab, garetosmab, pozelimab ,and

Regeneron’s oncology programs (including itscostimulatory bispecific portfolio) ;thelikelihood andtiming ofachieving anyoftheanticipated milestones described inthispresentation ;theextent towhich theresults from theresearch anddevelopment programs conducted

byRegeneron and/or itscollaborators may bereplicated inother studies and/or lead toadvancement ofproduct candidates toclinical trials, therapeutic applications, orregulatory approval ;ongoing regulatory obligations andoversight impacting Regeneron’s Products